CA2925008A1 - Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof - Google Patents
Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof Download PDFInfo
- Publication number
- CA2925008A1 CA2925008A1 CA2925008A CA2925008A CA2925008A1 CA 2925008 A1 CA2925008 A1 CA 2925008A1 CA 2925008 A CA2925008 A CA 2925008A CA 2925008 A CA2925008 A CA 2925008A CA 2925008 A1 CA2925008 A1 CA 2925008A1
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- composition
- epinephrine
- group
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 84
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 title claims abstract description 55
- 229930182837 (R)-adrenaline Natural products 0.000 title claims abstract description 52
- 229960005139 epinephrine Drugs 0.000 title claims abstract description 52
- 238000000034 method Methods 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 63
- 239000002738 chelating agent Substances 0.000 claims abstract description 23
- 239000007924 injection Substances 0.000 claims abstract description 19
- 238000002347 injection Methods 0.000 claims abstract description 19
- 229910052751 metal Inorganic materials 0.000 claims abstract description 16
- 239000002184 metal Substances 0.000 claims abstract description 16
- 239000003755 preservative agent Substances 0.000 claims description 36
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical group OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 150000001875 compounds Chemical class 0.000 claims description 20
- 239000000243 solution Substances 0.000 claims description 17
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 16
- 230000002335 preservative effect Effects 0.000 claims description 16
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 15
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 claims description 15
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 claims description 11
- 229960001802 phenylephrine Drugs 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 10
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 9
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 9
- 230000003444 anaesthetic effect Effects 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 8
- 229960004308 acetylcysteine Drugs 0.000 claims description 8
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
- 229960004194 lidocaine Drugs 0.000 claims description 8
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 8
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 claims description 7
- 229960001484 edetic acid Drugs 0.000 claims description 7
- OZWKMVRBQXNZKK-UHFFFAOYSA-N ketorolac Chemical compound OC(=O)C1CCN2C1=CC=C2C(=O)C1=CC=CC=C1 OZWKMVRBQXNZKK-UHFFFAOYSA-N 0.000 claims description 7
- 229960004752 ketorolac Drugs 0.000 claims description 7
- 229960004791 tropicamide Drugs 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 206010066373 Floppy iris syndrome Diseases 0.000 claims description 5
- 230000007170 pathology Effects 0.000 claims description 5
- 239000008223 sterile water Substances 0.000 claims description 5
- 108010024636 Glutathione Proteins 0.000 claims description 4
- 241001465754 Metazoa Species 0.000 claims description 4
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- 235000010323 ascorbic acid Nutrition 0.000 claims description 4
- 229960005070 ascorbic acid Drugs 0.000 claims description 4
- 239000011668 ascorbic acid Substances 0.000 claims description 4
- ZBPLOVFIXSTCRZ-UHFFFAOYSA-N bromfenac Chemical compound NC1=C(CC(O)=O)C=CC=C1C(=O)C1=CC=C(Br)C=C1 ZBPLOVFIXSTCRZ-UHFFFAOYSA-N 0.000 claims description 4
- 229960003655 bromfenac Drugs 0.000 claims description 4
- 229960001259 diclofenac Drugs 0.000 claims description 4
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 229960002390 flurbiprofen Drugs 0.000 claims description 4
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 229960003180 glutathione Drugs 0.000 claims description 4
- 235000003969 glutathione Nutrition 0.000 claims description 4
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 4
- 229960000991 ketoprofen Drugs 0.000 claims description 4
- 229960004919 procaine Drugs 0.000 claims description 4
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 claims description 4
- 229960003981 proparacaine Drugs 0.000 claims description 4
- 239000007921 spray Substances 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 229960002372 tetracaine Drugs 0.000 claims description 4
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 208000002177 Cataract Diseases 0.000 claims description 3
- 208000010412 Glaucoma Diseases 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims description 3
- 229960003072 epinephrine hydrochloride Drugs 0.000 claims description 3
- 239000003889 eye drop Substances 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 2
- 229940012356 eye drops Drugs 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims description 2
- 210000001525 retina Anatomy 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 239000008365 aqueous carrier Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 abstract description 8
- 239000000126 substance Substances 0.000 description 17
- 238000001356 surgical procedure Methods 0.000 description 10
- 239000000047 product Substances 0.000 description 8
- 210000001508 eye Anatomy 0.000 description 7
- 238000004108 freeze drying Methods 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- -1 anesthetic(s) (e.g. Chemical class 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 4
- 239000008227 sterile water for injection Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010066366 Toxic anterior segment syndrome Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000003855 balanced salt solution Substances 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 208000013299 intraoperative floppy iris syndrome Diseases 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 238000005192 partition Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical group CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 229940035674 anesthetics Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003193 general anesthetic agent Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- RPHLQSHHTJORHI-UHFFFAOYSA-N Adrenochrome Chemical compound O=C1C(=O)C=C2N(C)CC(O)C2=C1 RPHLQSHHTJORHI-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- SHWNNYZBHZIQQV-UHFFFAOYSA-J EDTA monocalcium diisodium salt Chemical compound [Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O SHWNNYZBHZIQQV-UHFFFAOYSA-J 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010022948 Iris atrophy Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- 206010040030 Sensory loss Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000007872 degassing Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229940124274 edetate disodium Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000871 endothelium corneal Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 108010014606 glutathione-bicarbonate-Ringer solution Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 description 1
- 150000008040 ionic compounds Chemical class 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- AWNVVAMWLMUZOZ-UHFFFAOYSA-J magnesium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Mg+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O AWNVVAMWLMUZOZ-UHFFFAOYSA-J 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000013110 organic ligand Substances 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts, ocular implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D25/00—Details of other kinds or types of rigid or semi-rigid containers
- B65D25/02—Internal fittings
- B65D25/04—Partitions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Mechanical Engineering (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361886269P | 2013-10-03 | 2013-10-03 | |
| US61/886,269 | 2013-10-03 | ||
| US201361892872P | 2013-10-18 | 2013-10-18 | |
| US61/892,872 | 2013-10-18 | ||
| US201461947778P | 2014-03-04 | 2014-03-04 | |
| US61/947,778 | 2014-03-04 | ||
| PCT/US2014/059077 WO2015051264A1 (en) | 2013-10-03 | 2014-10-03 | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2925008A1 true CA2925008A1 (en) | 2015-04-09 |
Family
ID=52779188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2925008A Abandoned CA2925008A1 (en) | 2013-10-03 | 2014-10-03 | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US10993921B2 (enExample) |
| EP (1) | EP3052095A4 (enExample) |
| JP (2) | JP2016532723A (enExample) |
| KR (1) | KR20160070077A (enExample) |
| AU (2) | AU2014329412B2 (enExample) |
| BR (1) | BR112016007328A2 (enExample) |
| CA (1) | CA2925008A1 (enExample) |
| IL (1) | IL244687A0 (enExample) |
| MX (1) | MX2016004257A (enExample) |
| WO (1) | WO2015051264A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015051264A1 (en) | 2013-10-03 | 2015-04-09 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof |
| TWI705812B (zh) | 2014-12-01 | 2020-10-01 | 奥默羅斯公司 | 用於抑制術後眼睛炎性病況的抗炎和散瞳前房溶液 |
| US20170189352A1 (en) | 2015-03-13 | 2017-07-06 | Par Pharmaceutical, Inc. | Epinephrine formulations |
| WO2017218918A1 (en) | 2016-06-17 | 2017-12-21 | Ys Pharmtech | Stabilization of epinephrine formulations |
| AU2017315757A1 (en) * | 2016-08-25 | 2019-03-07 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
| US20180318319A1 (en) | 2017-05-04 | 2018-11-08 | Ocular Science, Inc. | Compositions and Methods for Treating Eyes and Methods of Preparation |
| EP3687475A4 (en) * | 2017-09-26 | 2021-07-28 | YS Pharmtech | STABILIZATION OF EPINEPHRIN FORMULATIONS |
| WO2019182745A1 (en) | 2018-03-19 | 2019-09-26 | Bryn Pharma, LLC | Epinephrine spray formulations |
| WO2019183416A1 (en) | 2018-03-23 | 2019-09-26 | Nevakar Inc. | Epinephrine compositions and containers |
| US11071724B2 (en) | 2019-05-17 | 2021-07-27 | Ocular Science, Inc. | Compositions and methods for treating presbyopia |
| US20230277694A1 (en) * | 2022-03-04 | 2023-09-07 | Harrow Ip, Llc | Ophthalmic dye composition and method for administering same |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3808317A (en) * | 1969-10-29 | 1974-04-30 | Alcon Labor Inc | Stabilized aqueous borate complexes of biologically active catechol amines |
| US4590210A (en) * | 1979-03-09 | 1986-05-20 | Langham Maurice E | Compositions for treatment of ocular hypertension |
| US4525346A (en) * | 1981-09-28 | 1985-06-25 | Alcon Laboratories, Inc. | Aqueous antimicrobial ophthalmic solutions |
| US4550022A (en) * | 1981-10-05 | 1985-10-29 | Alcon Laboratories, Inc. | Tissue irrigating solution |
| CA2002643A1 (en) * | 1988-11-09 | 1990-05-09 | Maryjane Helenek | Antioxidant-free epinephrine solution for ophthalmic use |
| NL9102148A (nl) * | 1991-12-20 | 1993-07-16 | Dsm Nv | Copolymeer van lacton en carbonaat en werkwijze voor het verkrijgen ervan. |
| AU5405894A (en) * | 1992-10-21 | 1994-05-09 | Alcon Laboratories, Inc. | Composition for irrigating intraocular tissues and maintaining mydriasis during intraocular surgery |
| US5654337A (en) | 1995-03-24 | 1997-08-05 | II William Scott Snyder | Topical formulation for local delivery of a pharmaceutically active agent |
| US5709852A (en) | 1995-12-05 | 1998-01-20 | Basf Corporation | Ethylene oxide/propylene oxide/ethylene oxide (EO/PO/EO) triblock copolymer carrier blends |
| EP0958355A1 (en) | 1996-07-23 | 1999-11-24 | Wilson Trafton Crandall | Transdermal transport of molecules |
| FR2779061B1 (fr) * | 1998-04-14 | 2004-08-20 | Pharmatop | Nouveau procede de stabilisation de composes phenoliques et les compositions pharmaceutiques en resultant |
| DE19859427A1 (de) | 1998-12-22 | 2000-06-29 | Beiersdorf Ag | Kosmetische oder pharmazeutische lecithinhaltige Gele oder niedrigviskose, lecithinhaltige O/W-Mikroemulsionen |
| US6562002B1 (en) * | 1999-02-16 | 2003-05-13 | Prismedical Corporation | Single dose delivery device |
| WO2002026223A2 (en) * | 2000-09-29 | 2002-04-04 | Board Of Trustees Operating Michigan State University | Catecholamine pharmaceutical compositions and methods |
| FR2833493B1 (fr) * | 2001-12-18 | 2005-09-23 | Ioltechnologie Production | Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble |
| CA2488976C (en) * | 2002-06-28 | 2009-08-25 | Advanced Inhalation Research, Inc. | Inhalable epinephrine |
| SI1534313T1 (sl) | 2002-07-30 | 2013-03-29 | Omeros Corporation | Oftalmološke raztopine in postopek za izpiranje |
| US7700076B2 (en) | 2002-10-25 | 2010-04-20 | Foamix, Ltd. | Penetrating pharmaceutical foam |
| US20050176823A1 (en) | 2004-02-10 | 2005-08-11 | Diaz Robert L. | Intra-operative procedure for post-operative pain control |
| FR2882930B1 (fr) | 2005-03-09 | 2009-03-27 | Walid Katib | Nouvelles compositions ophtalmologiques et leur mode d'utilisation |
| DE102005038368A1 (de) | 2005-08-13 | 2007-02-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Doppelkammer-Behälter zur Lyophilisation, Verfahren zu dessen Befüllung und dessen Verwendung |
| US20070196324A1 (en) | 2006-02-01 | 2007-08-23 | Keefe Candace R | Cellulite skin treatment methods and compositions |
| US10022339B2 (en) | 2006-04-21 | 2018-07-17 | The Procter & Gamble Company | Compositions and methods useful for treatment of respiratory illness |
| US20080269347A1 (en) * | 2006-09-28 | 2008-10-30 | Azopharma, Inc. | Epinephrine formulations |
| US20090017120A1 (en) | 2007-03-23 | 2009-01-15 | Humco Holding Group, Inc. | Phase stable lecithin organogel composition |
| US8323695B2 (en) | 2007-08-13 | 2012-12-04 | Mcneil-Ppc, Inc. | Method for stabilizing phenylephrine |
| TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
| JP6073552B2 (ja) | 2008-11-14 | 2017-02-01 | アーチャー−ダニエルズ−ミッドランド カンパニー | オルガノゲル組成物及び製造方法 |
| CN101444481A (zh) | 2009-01-06 | 2009-06-03 | 河北科技大学 | 不含抑菌剂的托吡卡胺滴眼液及其制备方法 |
| MX2011012732A (es) | 2009-06-04 | 2012-02-28 | Alk Ag | Composicion estabilizada que comprende por lo menos un compuesto adrenergico. |
| WO2011156803A2 (en) | 2010-06-11 | 2011-12-15 | Transdel Pharmaceuticals, Inc. | Anti-cellulite composition and method of treating cellulite |
| AU2013201465B2 (en) | 2012-10-24 | 2016-03-03 | Rayner Intraocular Lenses Limited | Stable preservative-free mydriatic and anti-inflammatory solutions for injection |
| KR20140112825A (ko) | 2013-03-14 | 2014-09-24 | 삼성전자주식회사 | 전자 장치의 전자 결제 방법 및 장치 |
| US9849133B2 (en) | 2013-06-18 | 2017-12-26 | Eton Pharmaceuticals, Inc. | Pharmaceutical formulations of xanthine or xanthine derivatives, and their use |
| WO2015006299A1 (en) | 2013-07-08 | 2015-01-15 | Imprimis Pharmaceuticals, Inc. | Pharmaceutical formulations of tranexamic acid and their use |
| WO2015051264A1 (en) | 2013-10-03 | 2015-04-09 | Imprimis Pharmaceuticals, Inc. | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricatiing thereof |
| AU2017315757A1 (en) | 2016-08-25 | 2019-03-07 | Harrow Ip, Llc | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof |
-
2014
- 2014-10-03 WO PCT/US2014/059077 patent/WO2015051264A1/en not_active Ceased
- 2014-10-03 JP JP2016546889A patent/JP2016532723A/ja active Pending
- 2014-10-03 EP EP14851190.0A patent/EP3052095A4/en not_active Withdrawn
- 2014-10-03 KR KR1020167009782A patent/KR20160070077A/ko not_active Ceased
- 2014-10-03 CA CA2925008A patent/CA2925008A1/en not_active Abandoned
- 2014-10-03 AU AU2014329412A patent/AU2014329412B2/en active Active
- 2014-10-03 MX MX2016004257A patent/MX2016004257A/es unknown
- 2014-10-03 BR BR112016007328A patent/BR112016007328A2/pt not_active IP Right Cessation
- 2014-10-03 US US14/506,120 patent/US10993921B2/en active Active
-
2016
- 2016-03-21 IL IL244687A patent/IL244687A0/en unknown
- 2016-08-19 US US15/241,958 patent/US20160354308A1/en not_active Abandoned
- 2016-08-25 US US15/247,524 patent/US11045432B2/en active Active
-
2019
- 2019-05-08 JP JP2019088480A patent/JP2019142964A/ja active Pending
-
2020
- 2020-05-08 AU AU2020203044A patent/AU2020203044A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/330,023 patent/US20210275471A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20210275471A1 (en) | 2021-09-09 |
| WO2015051264A8 (en) | 2016-04-07 |
| MX2016004257A (es) | 2016-08-17 |
| US20170049721A1 (en) | 2017-02-23 |
| AU2014329412A1 (en) | 2016-05-05 |
| JP2019142964A (ja) | 2019-08-29 |
| US20160354308A1 (en) | 2016-12-08 |
| EP3052095A1 (en) | 2016-08-10 |
| JP2016532723A (ja) | 2016-10-20 |
| IL244687A0 (en) | 2016-04-21 |
| EP3052095A4 (en) | 2017-07-05 |
| US11045432B2 (en) | 2021-06-29 |
| AU2014329412B2 (en) | 2020-02-27 |
| KR20160070077A (ko) | 2016-06-17 |
| AU2020203044A1 (en) | 2020-05-28 |
| WO2015051264A1 (en) | 2015-04-09 |
| BR112016007328A2 (pt) | 2017-08-01 |
| US10993921B2 (en) | 2021-05-04 |
| US20150119440A1 (en) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210275471A1 (en) | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| US10285957B2 (en) | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| ES3040229T3 (en) | Stable preservative-free mydriatic and anti-inflammatory solutions for injection | |
| US8722738B2 (en) | Acetycysteine compositions and methods of use thereof | |
| JP2019517578A (ja) | 異常な新生血管形成を伴う眼疾患を処置するためにニンテダニブを使用する組成物および方法 | |
| JPH10502085A (ja) | Ｉｏｐを制御するための医薬を含有する眼内潅注溶液 | |
| US20210346318A1 (en) | Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof | |
| JPH09506620A (ja) | 非ステロイド抗炎症剤を含有する改良された眼内洗浄溶液 | |
| US20240058320A1 (en) | Mydriatic compositions and methods for fabricating thereof | |
| JP2022531670A (ja) | インスリンプレミックスの配合物と製品、それを調製する方法、及びそれを使用する方法 | |
| US20250268976A1 (en) | Broad-spectrum peptoids for treatment or prevention of wound infections, and compositions and methods of use thereof | |
| WO2023209731A1 (en) | Injectable liquid or lyophilized powder dosage forms of selexipag and their method of preparation | |
| WO2005041977A2 (en) | Process for producing injectable gabapentin compositions | |
| JPH0386818A (ja) | 白内障予防治療剤 | |
| MXPA94003569A (en) | Stable quinolone and naphthyridine premix formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190920 |
|
| FZDE | Discontinued |
Effective date: 20220223 |